Transplant Complications Drug Development Pipeline Review, 2018
Summary
GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.
Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously.
These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.
Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.
This report “Transplant Complications Drug Development Pipeline Review, 2018”, provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
- 2.1 Transplant Complications Report Coverage
- 2.2 Graft Versus Host Disease (GVHD) - Overview
- 2.3 Liver Transplant Rejection - Overview
- 2.4 Kidney Transplant Rejection - Overview
- 2.5 Lung Transplant Rejection - Overview
- 3 Therapeutics Development
- 3.1 Graft Versus Host Disease (GVHD)
- 3.2 Liver Transplant Rejection
- 3.3 Kidney Transplant Rejection
- 3.4 Lung Transplant Rejection
- 4 Therapeutics Assessment
- 4.1 Graft Versus Host Disease (GVHD)
- 4.2 Liver Transplant Rejection
- 4.3 Kidney Transplant Rejection
- 4.4 Lung Transplant Rejection
- 5 Companies Involved in Therapeutics Development
- 5.1 Graft Versus Host Disease (GVHD)
- 5.2 Liver Transplant Rejection
- 5.3 Kidney Transplant Rejection
- 5.4 Lung Transplant Rejection
- 6 Dormant Projects
- 6.1 Graft Versus Host Disease (GVHD)
- 6.2 Liver Transplant Rejection
- 6.3 Kidney Transplant Rejection
- 6.4 Lung Transplant Rejection
- 7 Discontinued Products
- 7.1 Graft Versus Host Disease (GVHD)
- 7.2 Liver Transplant Rejection
- 7.3 Kidney Transplant Rejection
- 8 Product Development Milestones
- 8.1 Graft Versus Host Disease (GVHD)
- 8.2 Liver Transplant Rejection
- 8.3 Kidney Transplant Rejection
- 8.4 Lung Transplant Rejection
- 9 Appendix
- 9.1 Methodology
- 9.2 Coverage
- 9.3 Secondary Research
- 9.4 Primary Research
- 9.5 Expert Panel Validation
- 9.6 Contact Us
- 9.7 Disclaimer
- 1.1 List of Tables
- Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD)
- Table 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)
- Table 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
- Table 4: Products under Development by Companies, Graft Versus Host Disease (GVHD)
- Table 5: Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
- Table 6: Number of Products under Development for Liver Transplant Rejection
- Table 7: Number of Products under Development by Companies, Liver Transplant Rejection
- Table 8: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection
- Table 9: Products under Development by Companies, Liver Transplant Rejection
- Table 10: Products under Development by Universities/Institutes, Liver Transplant Rejection
- Table 11: Number of Products under Development for Kidney Transplant Rejection
- Table 12: Number of Products under Development by Companies, Kidney Transplant Rejection
- Table 13: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
- Table 14: Products under Development by Companies, Kidney Transplant Rejection
- Table 15: Products under Development by Universities/Institutes, Kidney Transplant Rejection
- Table 16: Number of Products under Development for Lung Transplant Rejection
- Table 17: Number of Products under Development by Companies, Lung Transplant Rejection
- Table 18: Products under Development by Companies, Lung Transplant Rejection
- Table 19: Number of Products by Stage and Target, Graft Versus Host Disease (GVHD)
- Table 20: Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD)
- Table 21: Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD)
- Table 22: Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD)
- Table 23: Number of Products by Stage and Target, Liver Transplant Rejection
- Table 24: Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection
- Table 25: Number of Products by Stage and Route of Administration, Liver Transplant Rejection
- Table 26: Number of Products by Stage and Molecule Type, Liver Transplant Rejection
- Table 27: Number of Products by Stage and Target, Kidney Transplant Rejection
- Table 28: Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection
- Table 29: Number of Products by Stage and Route of Administration, Kidney Transplant Rejection
- Table 30: Number of Products by Stage and Molecule Type, Kidney Transplant Rejection
- Table 31: Number of Products by Stage and Target, Lung Transplant Rejection
- Table 32: Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection
- Table 33: Number of Products by Stage and Route of Administration, Lung Transplant Rejection
- Table 34: Number of Products by Stage and Molecule Type, Lung Transplant Rejection
- Table 35: Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc
- Table 36: Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc
- Table 37: Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc
- Table 38: Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc
- Table 39: Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH
- Table 40: Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc
- Table 41: Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc
- Table 42: Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc
- Table 43: Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc
- Table 44: Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co
- Table 45: Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc
- Table 46: Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA
- Table 47: Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd
- Table 48: Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc
- Table 49: Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd
- Table 50: Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd
- Table 51: Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc
- Table 52: Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SA
- Table 53: Graft Versus Host Disease (GVHD) - Pipeline by enGene Inc
- Table 54: Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd
- Table 55: Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd
- Table 56: Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc
- Table 57: Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd
- Table 58: Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc
- Table 59: Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp
- Table 60: Graft Versus Host Disease (GVHD) - Pipeline by Inspyr Therapeutics Inc
- 1.2 List of Figures
- Figure 1: Number of Products under Development for Graft Versus Host Disease (GVHD)
- Figure 2: Number of Products under Development by Companies, Graft Versus Host Disease (GVHD)
- Figure 3: Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD)
- Figure 4: Number of Products under Development for Liver Transplant Rejection
- Figure 5: Number of Products under Development by Companies, Liver Transplant Rejection
- Figure 6: Number of Products under Development by Universities/Institutes, Liver Transplant Rejection
- Figure 7: Number of Products under Development for Kidney Transplant Rejection
- Figure 8: Number of Products under Development by Companies, Kidney Transplant Rejection
- Figure 9: Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
- Figure 10: Number of Products under Development for Lung Transplant Rejection
- Figure 11: Number of Products under Development by Companies, Lung Transplant Rejection
- Figure 12: Number of Products by Top 10 Targets, Graft Versus Host Disease (GVHD)
- Figure 13: Number of Products by Stage and Top 10 Targets, Graft Versus Host Disease (GVHD)
- Figure 14: Number of Products by Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)
- Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD)
- Figure 16: Number of Products by Routes of Administration, Graft Versus Host Disease (GVHD)
- Figure 17: Number of Products by Stage and Routes of Administration, Graft Versus Host Disease (GVHD)
- Figure 18: Number of Products by Top 10 Molecule Types, Graft Versus Host Disease (GVHD)
- Figure 19: Number of Products by Stage and Top 10 Molecule Types, Graft Versus Host Disease (GVHD)
- Figure 20: Number of Products by Top 10 Targets, Liver Transplant Rejection
- Figure 21: Number of Products by Stage and Top 10 Targets, Liver Transplant Rejection
- Figure 22: Number of Products by Top 10 Mechanism of Actions, Liver Transplant Rejection
- Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Liver Transplant Rejection
- Figure 24: Number of Products by Routes of Administration, Liver Transplant Rejection
- Figure 25: Number of Products by Stage and Routes of Administration, Liver Transplant Rejection
- Figure 26: Number of Products by Molecule Types, Liver Transplant Rejection
- Figure 27: Number of Products by Stage and Molecule Types, Liver Transplant Rejection
- Figure 28: Number of Products by Top 10 Targets, Kidney Transplant Rejection
- Figure 29: Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection
- Figure 30: Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection
- Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection
- Figure 32: Number of Products by Routes of Administration, Kidney Transplant Rejection
- Figure 33: Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection
- Figure 34: Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection
- Figure 35: Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection
- Figure 36: Number of Products by Targets, Lung Transplant Rejection
- Figure 37: Number of Products by Stage and Targets, Lung Transplant Rejection
- Figure 38: Number of Products by Mechanism of Actions, Lung Transplant Rejection
- Figure 39: Number of Products by Stage and Mechanism of Actions, Lung Transplant Rejection
- Figure 40: Number of Products by Routes of Administration, Lung Transplant Rejection
- Figure 41: Number of Products by Stage and Routes of Administration, Lung Transplant Rejection
- Figure 42: Number of Products by Molecule Types, Lung Transplant Rejection
- Figure 43: Number of Products by Stage and Molecule Types, Lung Transplant Rejection